syreon Middle East

QALYs: 10.50

+ - - Costs (EGP): 32,161

ICER: Dominant

Cost-Effectiveness and budget impact of Bariatric Surgeries to Reduce Obesity in Egypt

Ahmad Fasseeh^{1,2}, Kareem El-Fass², Ahmed Seyam³, Noura Maher³, Rania Abdelaziz³, Balazs Nagy^{4,5}

- Faculty of Pharmacy Alexandria University
- Syreon Middle East, Alexandria, Egypt
- Universal health insurance Authority, Cairo, Egypt 3.

- Semmelweis University, Budapest, Hungary
- Syreon Research Institute, Budapest, Hungary

INTRODUCTION

Obesity is a critical public health issue in Egypt, contributing to 1 out of every 5 deaths. With approximately 40% of the population classified as obese (Body Mass Index > 30), it is a major risk factor for the development of several lifethreatening conditions, including diabetes mellitus, hypertension, obstructive sleep apnea, and fatty liver disease.⁽¹⁾ The economic burden of obesity in Egypt is staggering, costing the healthcare system an estimated 62 billion Egyptian pounds (EGP) in 2020.⁽²⁾


RESULTS

All surgical interventions **dominated** no intervention, proving both **more** effective and cost-saving. Average patient survival increased by 3.4 years with laparoscopic gastric sleeve, 3.9 years with Roux-en-Y, and 3.8 years with one-anastomosis gastric bypass. Additionally, event-free survival for comorbidities improved in surgical groups. Below is the quality adjusted life years (QALYs), costs, net-monetary benefits (NMB) with the different interventions.

One anastomosis gastric bypass

This study aims to evaluate the **cost-effectiveness** of bariatric surgery, weighing its long-term benefits against the financial and medical risks, as well as the **budget impact** of adopting the technology to inform reimbursement decisions and improve healthcare resource allocation.

- NMB: 220,746 METHODS Laparoscopic Roux-en-Y Gastric Bypass Laparoscopic Sleeve Gastrectomy QALYs: 10.63 Bariatric QALYs: 10.19 Surgery Costs (EGP): 322,566 -Costs (EGP): 315,861 **Cohort Generator** Options ICER: Dominant --ICER: Dominant nput: 51 patient NMB: 236,971 ·--' characteristics Cohort - NMB: 206,844 Output: Cohort generation, generation (Adults ≥ 18 years, obese ≥ 30 BMI), derived from statistical distributions **Diabetes modelling** No Surgery **Diabetes was modeled so** QALYs: 7.87 that diabetic patients go Model starts here **16 Comorbidities** through the UHIA **Patient-level** Costs (EGP): 331,448 treatment protocol and (Each is simulated as a seperate Markov simulation comorbidities are model) modeled accordingly model Diabetes Diabetic neuropathy



Methodology summary

Model type: Patient-level simulation model **Cohort:** Representing obese population in Egypt **Perspective:** Payer (Universal Health Insurance Authority of Egypt)

Time horizon: Lifetime

Year	1% of the eligible population	Budget Needed to cover 1%
2024	5711	329,107,892
2025	980	56,474,476
2026	3245	186,999,669
2027	8249	475,365,260
2028	10671	614,937,895

Table 1: Budget Impact in targeting 1% of the eligible population for metabolic surgery

CONCLUSION

Metabolic surgeries are **highly cost-effective** compared to no surgery. It is

Cycle lengths: 6 months

Intervention: Laparoscopic (Sleeve gastrectomy/Roux-en-Y/One anastomosis gastric bypass)/No treatment

Mortality: General and disease-specific mortalities considered

Outcomes:

Average cost per patient

QALYs per patient

Life years per patient (average life expectancy)

Time-to first event

Co-morbidities in each arm

Number of acute events: Myocardial infarction, Stroke, DKA, Hypoglycemia Years with chronic conditions: Hypertension, Diabetes, Dyslipidemia

Note: Costs and QALYs are discounted at 3.5%

- dominant for most patients (cost less than no surgery and yield more benefits).
- 2. The cost of the intervention is paid upfront, and the benefits are harvested over several years.
- 3. The eligible population is huge (Year 1: 571,000. Year 5: 1,000,000).
- 4. Therefore, it is challenging to fund the surgery for all existing eligible population.
- 5. However, the health and financial benefits from the surgery is great not to be reimbursed.
- 6. So, limiting reimbursement to those patients who will yield more QALYs seems to be the plausible approach.

REFERENCES

1. Aboulghate M, Elaghoury A, Elebrashy I, Elkafrawy N, Elshishiney G, Abul-Magd E, et al. The Burden of Obesity in Egypt. Front Public Health. 2021;9:718978-.

2. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann Intern Med. 1991;115(12):956-61.